Sumanta K Pal1, Siraj M Ali2, Evgeny Yakirevich3, Daniel M Geynisman4, Jose A Karam5, Julia A Elvin2, Garrett M Frampton2, Xuan Huang6, Douglas I Lin7, Mark Rosenzweig2, Doron Lipson2, Philip J Stephens2, Jeffrey S Ross8, Vincent A Miller2, Neeraj Agarwal9, Brian Shuch10, Toni K Choueiri11, Jon H Chung2. 1. Department of Medical Oncology & Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Electronic address: spal@coh.org. 2. Foundation Medicine, Cambridge, MA, USA. 3. Department of Pathology, Rhode Island Hospital and Alpert Medical School of Brown University, Providence, RI, USA. 4. Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA. 5. Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Division of Hematology and Oncology, University Hospitals Case Medical Center & Case Western Reserve University, Cleveland, OH, USA. 7. Department of Pathology, Beth Israel Deaconess Medical Center, Chelsea, MA, USA. 8. Foundation Medicine, Cambridge, MA, USA; Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY, USA. 9. Division of Medical Oncology, Department of Internal Medicine, University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA. 10. Division of Urology, Yale Cancer Institute, New Haven, CT, USA. 11. Division of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA. Electronic address: toni_choueiri@dfci.harvard.edu.
Abstract
BACKGROUND: Papillary renal cell carcinoma (PRCC) is a rare subset of RCC. The Cancer Genome Atlas (TCGA) data largely reflect localized disease, and there are limited data for advanced PRCC. OBJECTIVE: To characterize the frequency of genomic alterations (GAs) in patients with advanced PRCC for whom comprehensive genomic profiling (CGP) was performed in the context of routine clinical care. DESIGN, SETTING, AND PARTICIPANTS: Formalin-fixed, paraffin-embedded tissue was obtained for 169 consecutive patients with confirmed PRCC. DNA was extracted and comprehensive genomic profiling was performed in a certified central laboratory. MEASUREMENTS: Hybrid-capture, adaptor ligation-based libraries of up to 315 genes were sequenced to a median coverage of 648×. All classes of GAs were identified, including substitutions, insertions/deletions, copy number alterations, and rearrangements. RESULTS AND LIMITATIONS: From 169 patients, either primary tumor tissue (102 patients, 60%) or metastatic tissue (67 patients, 40%) was collected. In patients with type 1 PRCC, commonly altered genes were MET (33%; 8 activating mutations, 5 amplifications at >6 copies), TERT (30%), CDKN2A/B (13%), and EGFR (8%). In patients with type 2 PRCC, commonly altered genes were CDKN2A/B (18%), TERT (18%), NF2 (13%), and FH (13%); MET GAs (5 mutations, 3 amplifications) were observed in 7% of type 2 cases. Notable differences from TCGA data include higher frequencies of MET, NF2, and CDKN2A/B GAs, association of alterations in SWI/SNF complex genes with type 2 PRCC, and observation of frequent CDKN2A/B alterations in both type 1 and type 2 disease. CONCLUSIONS: Both the current study and the TCGA experience represent similarly sized cohorts of patients with PRCC. Key differences in GA frequency probably underscore the marked difference in stage distribution between these data sets. These results may inform planned precision medicine trials for metastatic PRCC. PATIENT SUMMARY: Papillary renal cell carcinoma (PRCC) is a rare subtype of kidney cancer, and understanding of the biology of advanced PRCC is limited. This report highlights some of the unique biologic features of PRCC that may inform on future use of targeted therapies for the treatment of metastatic disease.
BACKGROUND:Papillary renal cell carcinoma (PRCC) is a rare subset of RCC. The Cancer Genome Atlas (TCGA) data largely reflect localized disease, and there are limited data for advanced PRCC. OBJECTIVE: To characterize the frequency of genomic alterations (GAs) in patients with advanced PRCC for whom comprehensive genomic profiling (CGP) was performed in the context of routine clinical care. DESIGN, SETTING, AND PARTICIPANTS: Formalin-fixed, paraffin-embedded tissue was obtained for 169 consecutive patients with confirmed PRCC. DNA was extracted and comprehensive genomic profiling was performed in a certified central laboratory. MEASUREMENTS: Hybrid-capture, adaptor ligation-based libraries of up to 315 genes were sequenced to a median coverage of 648×. All classes of GAs were identified, including substitutions, insertions/deletions, copy number alterations, and rearrangements. RESULTS AND LIMITATIONS: From 169 patients, either primary tumor tissue (102 patients, 60%) or metastatic tissue (67 patients, 40%) was collected. In patients with type 1 PRCC, commonly altered genes were MET (33%; 8 activating mutations, 5 amplifications at >6 copies), TERT (30%), CDKN2A/B (13%), and EGFR (8%). In patients with type 2 PRCC, commonly altered genes were CDKN2A/B (18%), TERT (18%), NF2 (13%), and FH (13%); MET GAs (5 mutations, 3 amplifications) were observed in 7% of type 2 cases. Notable differences from TCGA data include higher frequencies of MET, NF2, and CDKN2A/B GAs, association of alterations in SWI/SNF complex genes with type 2 PRCC, and observation of frequent CDKN2A/B alterations in both type 1 and type 2 disease. CONCLUSIONS: Both the current study and the TCGA experience represent similarly sized cohorts of patients with PRCC. Key differences in GA frequency probably underscore the marked difference in stage distribution between these data sets. These results may inform planned precision medicine trials for metastatic PRCC. PATIENT SUMMARY:Papillary renal cell carcinoma (PRCC) is a rare subtype of kidney cancer, and understanding of the biology of advanced PRCC is limited. This report highlights some of the unique biologic features of PRCC that may inform on future use of targeted therapies for the treatment of metastatic disease.
Authors: Sabina Signoretti; Catherine J Wu; Sachet A Shukla; Toni K Choueiri; David A Braun; Yue Hou; Ziad Bakouny; Miriam Ficial; Miriam Sant' Angelo; Juliet Forman; Petra Ross-Macdonald; Ashton C Berger; Opeyemi A Jegede; Liudmilla Elagina; John Steinharter; Maxine Sun; Megan Wind-Rotolo; Jean-Christophe Pignon; Andrew D Cherniack; Lee Lichtenstein; Donna Neuberg; Paul Catalano; Gordon J Freeman; Arlene H Sharpe; David F McDermott; Eliezer M Van Allen Journal: Nat Med Date: 2020-05-29 Impact factor: 53.440
Authors: Shannon M White; Maria Laura Avantaggiati; Ivan Nemazanyy; Cristina Di Poto; Yang Yang; Mario Pende; Geoffrey T Gibney; Habtom W Ressom; Jeffery Field; Michael B Atkins; Chunling Yi Journal: Dev Cell Date: 2019-05-06 Impact factor: 12.270
Authors: Alessa Fischer; Lorenz Bankel; Stefanie Hiltbrunner; Markus Rechsteiner; Jan H Rüschoff; Elisabeth Jane Rushing; Christian Britschgi; Alessandra Curioni-Fontecedro Journal: Target Oncol Date: 2022-09-22 Impact factor: 4.864
Authors: Adam J Schoenfeld; Joseph M Chan; Daisuke Kubota; Hiroki Sato; Hira Rizvi; Yahya Daneshbod; Jason C Chang; Paul K Paik; Michael Offin; Maria E Arcila; Monika A Davare; Ujwal Shinde; Dana Pe'er; Natasha Rekhtman; Mark G Kris; Romel Somwar; Gregory J Riely; Marc Ladanyi; Helena A Yu Journal: Clin Cancer Res Date: 2020-01-07 Impact factor: 12.531
Authors: Sumanta K Pal; Catherine Tangen; Ian M Thompson; Naomi Balzer-Haas; Daniel J George; Daniel Y C Heng; Brian Shuch; Mark Stein; Maria Tretiakova; Peter Humphrey; Adebowale Adeniran; Vivek Narayan; Georg A Bjarnason; Ulka Vaishampayan; Ajjai Alva; Tian Zhang; Scott Cole; Melissa Plets; John Wright; Primo N Lara Journal: Lancet Date: 2021-02-13 Impact factor: 79.321